29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) ...
Background Endocrine therapy (ET) plus CDK4/6 inhibitor is the mainstay for the management of estrogen receptor-positive (ER+)/HER2- negative (HER2–) metastatic breast cancer (mBC) as first-line therapy; however, tumors eventually develop …